MedTrace Logo

The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

NCT03140358 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-05-18

No results posted yet for this study

Summary

Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.

Conditions

  • Myopia

Interventions

DRUG

Atropine sulfate 0.01%

Atropine 0.01%

DRUG

Placebo

placebo

Sponsors & Collaborators

  • National Medical Research Council (NMRC), Singapore

    collaborator OTHER_GOV

  • Singapore National Eye Centre

    lead OTHER_GOV

Principal Investigators

  • Audrey Chia · Singapore National Eye Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-21
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03140358 on ClinicalTrials.gov